We evaluate the efficacy of the oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) in 71 refractory/relapsed multiple myeloma patients, including a prognostic analysis to predict both response and survival. Patients received thalidomide at escalating doses (200-800 mg/ day), daily cyclophosphamide (50 mg/day) and pulsed dexamethasone (40 mg/day, 4 days every 3 weeks). On an intentionto-treat basis and using the EBMT response criteria, 2% patients reached complete response (CR), 55% partial response (PR) and 26% minor response (MR) yielding a total response (CR þ PR þ MR) rate of 83% after 3 months of therapy. After 6 months of therapy, responses were maintained including a 10% CR. The 2-year progression free and overall survival were 57 and 66%, respectively. A favorable response was associated with b 2 microglobulin p4 mg/dl, platelets 480 Â 10 9 /l and nonrefractory disease. Regarding survival, low b 2 microglobulin (p4 mg/dl), age (p65 years) and absence of extramedullary myelomatous lesion were associated with a longer survival. Major adverse effects included constipation (24%), somnolence (18%), fatigue (17%) and infection (13%). Only 7% of patients developed a thrombo-embolic event. ThaCyDex is an oral regimen that induces a high response rate and long remissions, particularly in relapsing patients with b 2 microglobulin p4 mg/dl and p65 years.
Introduction
Despite the use of high-dose chemotherapy followed by stem cell rescue, multiple myeloma (MM) remains incurable at present. [1] [2] [3] Since virtually all patients ultimately relapse, there is an intensive search for new active drugs and therapeutic salvage strategies. [4] [5] [6] [7] [8] [9] [10] One of the most active and promising drugs for this subset of patients is thalidomide, which has provided an overall response rate of around 45%. [11] [12] [13] [14] [15] [16] [17] [18] In an attempt to increase this response rate, several groups, including our own, have investigated the efficacy of combining thalidomide with other agents. We designed a protocol (ThaCyDex) that includes thalidomide together with oral cyclophosphamide and dexamethasone. 19 The rationale for this combination was a favorable experience, in terms of disease control and low toxicity, with cyclophosphamide and steroids as palliative treatment in refractory MM patients, [20] [21] [22] and the potential synergistic effect of thalidomide combined with dexamethasone. 23 The combination of cyclophosphamide plus steroids was designed as 'a gentle approach' to treat an especially frail group of patients in whom treatment-related toxicity and the resultant morbidity/mortality are a major concern. 20 Our goal was to investigate the efficacy and toxicity of the oral combination of thalidomide, cyclophosphamide and dexamethasone in refractory/relapsed myeloma patients.
The preliminary results from a pilot study including 17 patients showed an overall response rate of 77%, including 53% of all cases with X50% M-component reduction. 19 In addition, the regimen was tolerated well and the number and severity of secondary effects were acceptable. Similar results have been reported by other groups with different combinations, [24] [25] [26] [27] [28] but the series of patients are usually small and, more importantly, the follow-up is too short to sustain definitive conclusions in the long-term effects of these treatments. Here, we report on extended experience with ThaCyDex including a total of 71 MM patients with refractory or relapsed MM. The global response rate reached was 89% (59% with X50% Mcomponent reduction). Moreover, response was durable with an event-free survival (EFS) of 57% at 30 months after start of therapy. In addition, we have identified independent prognostic factors to predict both response and survival following ThaCyDex treatment.
Materials and methods

Patients
Between April 2000 and November 2002, 71 consecutive eligible patients from 14 institutions, with relapsed/refractory MM, were included in the study after written informed consent. The diagnosis of MM was made according to standard definitions. The criteria for inclusion also required a life expectancy higher than 3 months and absence of irreversible organic deterioration. In addition, the treatment-free period had to be at least 1 month. Exclusion criteria were: (1) existence of a myelodysplastic syndrome or other neoplastic disease different from MM; (2) presence of clinical neurological abnormalities; (3) history of paralytic ileus; (4) presence of clinical liver dysfunction, uncontrolled infection, uncontrolled hypercalcemia or pregnancy; (5) presence of unrecoverable cytopenias (o0.5 granulocytes Â 10 9 /l, o30 platelets Â 10 9 /l); and (6) presence of uncontrollable diabetes mellitus. In addition, all patients younger than 70 years fitting the criteria for autologous or allogeneic transplant rescue were excluded from this protocol.
At inclusion, patients were separated into two groups: (1) relapse, if they had responded to previous therapy and had progressed after a plateau phase; (2) refractory, if they had progressed during initial therapy (primary refractory) or, after an initial response, they had progressed during salvage therapy (secondary refractory).
Therapeutic protocol
The therapeutic protocol included the oral administration of three different drugs, as previously described. 19 Thalidomide (Thalomid s ) was supplied in 100-mg capsules by Grü nenthal (Aachen, Germany) and was administered at night at an initial dose of 200 mg. If no secondary effects were present after the first week, the dose was increased to 400 mg per day. Afterwards, the dose was increased every 2 weeks for 4 weeks, up to a final maximum dose of 800 mg per day. In cases of grade X2 secondary effects, the dose was reduced until side effects ceased and the schedule was adjusted to accommodate patient symptoms. In cases of a favorable response and no important secondary effects, treatment was maintained indefinitely, tapering the dose to maintain it around 200 mg/day. Somnolence was considered to be the limiting side effect for increasing the dose.
Cyclophosphamide (Genoxal & , Prasfarma, Barcelona, Spain) was administered orally at a dosage of 50 mg/day. In case of neutropenia, dose was reduced or delayed every other day in order to maintain the granulocyte count X1.0 Â 10 9 /l. In cases of response, cyclophosphamide was maintained for at least 1 year.
Dexamethasone (Fortecortin & , Merck, Darmstadt, Germany) was given orally at a dose of 40 mg/day, for 4 days, every 3 weeks. If significant secondary side effects appeared, the dosage was reduced to 20 mg/day, 4 days every 3 weeks or substituted by oral prednisone at a dose of 25 mg/48 h. In cases of response and no important secondary effects, it was maintained indefinitely.
Evaluation
The pretreatment evaluation included complete blood counts, biochemical tests for renal and liver functions, electrophoresis of serum and urine, b 2 microglobulin and C-reactive protein. Bone marrow aspirates were obtained to determine the percentage of bone marrow plasma cells (BMPC) by morphology. In addition, the proliferative activity of BMPC, assessed by the number of cells in the S-phase, was analyzed by flow cytometry in 23 patients as previously described. 29 In total, 16 patients have available data on cytogenetic abnormalities both by conventional cytogenetics or fluorescence in situ hybridization. 30 Follow-up studies included the estimation of the monoclonal component in serum or urine every 2 weeks for the first 2 months, and subsequently by monthly determinations. Bone marrow examination was scheduled 6 months after the beginning of treatment.
Assessment of adverse effects
The primary end point of this study was to determine the response rate at 3 and 6 months after the beginning of therapy as well as the duration of responses and overall survival (OS). In addition, toxicity of the scheme was analyzed in all patients. A secondary objective was the analysis of prognostic factors influencing both response and survival. All 71 patients were evaluated for side effects, independent of the duration of treatment and response. All patients were evaluated every 2 weeks during the first 2 months and each month thereafter. The adverse events were documented through conventional interview and basic general and neurological physical examination. All adverse events were documented in the clinical file, as well as any clinical or laboratory abnormality detected, writing down the beginning date, evolution and the ending date, as well as if the treatment was interrupted or modified. All patients were specifically asked for the most common adverse events previously reported for thalidomide during the interviews. The protocol booklets specifically required to pay attention to a list of frequent reported symptoms, including constipation, weakness or fatigue, somnolence, tingling or numbness, dizziness, rash, mood changes or depression, incoordination, tremors and edema, nausea and headache. In case of neurological problems, a neurologist's help was required, including the use of muscle and nerve eletrophysiological tests and image proofs (CT, MRI). The OMS scales were used to evaluate the severity of the adverse event.
Assessment of response
Response was assessed according to the criteria used by Myeloma Subcommittee of EBMT. 31 A complete response (CR) was defined as (1) negative inmunofixation on both serum and urine maintained for a minimum of 6 weeks; (2) o5% plasma cells in a bone marrow aspirate; (3) no increase in the size or number of lytic bone lesions; and (4) disappearance of softtissue plasmacytomas. Partial response (PR) requires (1) a reduction of 50% or more of the M-component; (2) reduction in 24 h urinary light chain excretion either by 490% or to o200 mg; (3) in nonsecretory myeloma X50% reduction in plasma cells in a bone marrow aspirate; (4) a decrease of over 50% in the size of soft-tissue plasmacytomas (by radiography or clinical examination); and (5) no increase in the size or number of lytic bone lesions. Finally, minimal response (MR) requires (1) 25-49% reduction in M-component; (2) 50-89% reduction in 24 h urinary light chain excretion; (3) in nonsecretory myeloma 25-49% reduction in plasma cells in a bone marrow aspirate; (4) 25-49% reduction in the size of soft-tissue plasmacytomas; and (5) no increase in the size of number of lytic bone lesions. When the criteria for PR or MR were not fulfilled, the case was considered a treatment failure, with a distinction between no change (NC, o25% M-component reduction) and progressive disease (PD).
Relapse was defined as a reappearance of M-component by inmunofixation or electrophoresis, X5% of plasma cells in a bone marrow aspirate, development of new lytic bone lesions or new soft-tissue plasmacytomas or increase in the size or number of lytic bone lesions or hypercalcemia not attributable to any other cause.
OS was measured from the time of inclusion in the protocol to the moment of death, and EFS from the inclusion in the protocol to the moment in which a relapse, progression or death was observed.
Statistical analysis
A descriptive statistical analysis was performed after including all data on a FileMaker Pro database (Claris Corp., Santa Clara, CA, USA). Differences in clinical measurements were evaluated with the SPSS 11.0 statistical software for Windows (SPSS, Chicago, IL, USA). To estimate the significance of the differences between these values, the w 2 , T-Test, MannWhitney, ANOVA and Wilcoxon tests were used, according to the number of cases in every group. OS and EFS curves were analyzed according to the method of Kaplan and Meier. Multivariate analysis of prognostic factors for response and OS was carried out through a regression analysis (Coxreg, SPSS), considering those variables displaying a significant association with survival in the univariate analysis (Po0.05) or those for which prior studies had suggested a possible prognostic value. The stepwise regression method was discontinued when the P-value for entering an additional factor was above 0.05. The model was tested both by including the variables in a continuous manner (continuous model) and by grouping them into categories (dichotomous model).
Results
The main characteristics of the patients included in the study are shown in Table 1 . In total, 28 patients (39%) were in first relapse, with a median response duration of 12 months, while 12 patients were in second relapse and six in third or subsequent relapse. The remaining 25 patients had refractory disease (13 were primary resistant and 12 were secondary resistant). In all, 21 patients (32%), corresponding to 75% of those o65 years of age, had been treated with high-dose therapy followed by autologous peripheral blood stem cell transplantation prior to inclusion within the protocol, and 71% had received a high dose of dexamethasone. A high-risk cytogenetic abnormality (deletion of chromosome 13 or complex karyotype) was present in 10 of 16 cases analyzed. Cell cycle analysis by flow cytometry was performed on 23 patients and 39% of them showed X3% PC in the S-phase.
The median dose of thalidomide safely achieved was 600 mg/ day. The final doses achieved were: 800 mg/day in 39%; 600 mg/day in 19%; 400 mg/day in 19%; 300 mg/day in 8%; and 200 mg/day in 15%. However, most cases required a dosage reduction with the follow-up, and only two patients tolerated long-term doses of 800 mg/day. Thus, in long-surviving patients (41 year), 7% were receiving 800 mg/day, 14% 400 mg/day, 55% 200 mg/day and 24% 100 mg/day. The median final dosage for cyclophosphamide was 50 mg/48 h, while dexamethasone was always administered as scheduled, except in eight cases with intolerance, which was changed to prednisone.
Adverse effects
There were five deaths in the absence of overt myeloma progression, which were due to infectious complications in three cases (4%) and sudden death presumably due to arrhythmia in two patients (3%) who had also been diagnosed of previous severe cardiopathy. Three of these patients were in PR and two in MR when they suffered the complication terminating in death.
Overall, nine patients had to interrupt the protocol due to toxicity: five before the response was evaluated (early interruptions) and four after it was already assessed (late interruptions). Causes for the five early interruptions were: voluntary discontinuation due to discomfort (n ¼ 2), early death caused by concomitant infection (n ¼ 1), peripheral neuropathy (n ¼ 1) and severe somnolence (n ¼ 1). All these five patients were receiving 200 mg/day of thalidomide when the protocol was withdrawn. By contrast, late interruptions were caused by neuropathy (n ¼ 2) and fatigue (n ¼ 2) attributable to the protocol. Within these last cases, in two the therapy had failed, one had achieved a MR and one was in PR when ThaCyDex was completely suspended due to neurotoxicity; in this last case, the disease progressed 2 months after the protocol interruption.
Other adverse effects were generally moderate. Thus, secondary effects with an OMS score X2 were constipation (24%), somnolence (18%), fatigue (17%) and dizziness (8%). Seven patients (10%) developed grade 3/4 neutropenia, which was resolved after reducing the cyclophosphamide dosage. No other hematological toxicity was attributable to the protocol. Infection was noted in nine patients (13%) in the absence of progressive disease; four cases were grade 2 and were resolved with oral antibiotic therapy but five cases required hospitalization due to severity (OMS grade 3 or 4), including the three patients who died due to the complication. Peripheral neuropathy (OMS score X2) was 6% and minor. There was one case of meralgia paresthetica that rapidly improved with standard doses of carbamazepine without withdrawing thalidomide. Four patients experienced an increase in serum creatinine levels of ThaCyDex for refractory/relapsed multiple myeloma R García-Sanz et al more than 50% with respect to the initial value, but it was always attributable to the myeloma status. Six patients displayed hyperglycemia related to dexamethasone but it was always resolved with a change of diet and oral hypoglycemic agents with or without dexamethasone replacement by prednisone. In addition, two patients displayed proximal weakness, which was interpreted as steroid myopathy, which improved after replacing dexamethasone with prednisone.
Finally, five patients (7%) developed an episode of deep venous thrombosis (DVT), one of them with a thrombotic pulmonary embolism. All patients were treated with standard antithrombotic therapy with a favorable response and outcome. In addition, two patients with severe concomitant cardiopathy died suddenly due to arrhythmia related to heart disease.
No cases of skin toxicity or edema have been documented. In addition, only one case of tremor has been specifically documented in this study.
Response and survival
In all, 66 patients were evaluable for response. After 3 months of therapy, most patients (89%) responded to the therapy, since only six (9%) had progressed after the beginning of ThaCyDex and one patient displayed no changes with the treatment (Table 2 ). In an intention-to-treat analysis, the global response rate would have been 83% (59 out 71). Among the responders, one (2%) reached CR, and 37 (55%) achieved a PR. A total of 23 patients (26%) had MR (clinical improvement and reduction of the M-component between 25 and 49%).
The six patients who did not initially respond to the therapy displayed the following findings: all but one achieved some grade of reduction in the monoclonal component after 1-3 months of treatment, but they progressed thereafter -due to a reincrease in the M-component (n ¼ 2), development of new osteolytic lesions (n ¼ 2) or increase in the size of previous extramedullary myelomatous lesions (n ¼ 1). The sixth patient showed a continuous progression, with an increase in the M-component size (urine light chains) and development of renal failure once the therapy was begun.
After 6 months of therapy, most responses were maintained, although a small group (n ¼ 6) of patients progressed. Thus, the global response rate decreased to 68% (Table 2) . By contrast, in another three patients the response improved up to the complete clearance of the M-component, which resulted in a complete response rate of 10% (Table 2) .
With a mean follow-up of 1 Table 3 shows the univariate and multivariate analyses carried out to identify variables predicting the response to ThaCyDex after 6 months of therapy. A favorable response at this time was associated with a low b2 microglobulin (p4 mg/l), high hemoglobin (48 g/dl) and platelet counts (480 Â 10 9 /l), IgG isotype and disease relapse instead of refractory disease. On the Table 2 Response to ThaCyDex ThaCyDex for refractory/relapsed multiple myeloma R García-Sanz et al multivariate analysis, the only three independent variables capable of predicting a favorable response (complete, partial and minor) to ThaCyDex vs unfavorable response (early death, progressive disease or no changes) were b2 microglobulin o4 mg/dl, a platelet count higher than 80 Â 10 9 /l and nonrefractory disease. In addition, we also investigated some variables that have been reported as predictors of a poor response to thalidomide, such as the presence of plasmacytomas and a high number of lines of chemotherapy prior to the rescue therapy. These variables were certainly related to the response, but they failed to achieve statistically significant differences (Table 3) . A similar analysis was carried out at 3 months including all patients (even the five cases interrupting the therapy due to toxicity, which were considered unfavorable responders), and results were similar but, in this case, the presence of a non-IgG myeloma, hemoglobin lower than 8 g/dl and a time from the last chemotherapy lower than 12 months were selected as the main variables for predicting a good response. Table 4 shows the univariate and multivariate analysis of prognostic factors for OS (which was similar for EFS). Of interest is the fact that the best predictor for OS was the response to ThaCyDex (Figure 2 ), but it was not included in the final multivariate analysis because this factor was not available at the time when therapy began. Thus, the main pretreatment characteristics favoring a prolonged survival in MM patients treated with ThaCyDex were: b 2 microglobulin p4 mg/l, age p65 years, absence of extramedullary myelomatous lesions, hemoglobin 48 g/dl, normal LDH, ECOGo2 and nonrefractory disease. However, only the former variables retained an independent prognostic value on multivariable analyses.
Prognostic factors for response and survival
Discussion
The efficacy of thalidomide in refractory/relapsed patients is now indubitable. Its mechanism of action has not yet been completely resolved, but it may rely on an antiangiogenic effect, on downregulation in cytokine secretion (IFN-g, IL-2, IL-6, IL-1b, IL-10 and TNF), on modulation of cell surface molecules and stimulatory effect on natural killer cells. [32] [33] [34] MM patients with refractory/relapsed disease are frequently not candidates for intensive strategies since they have usually been heavily treated or they have advanced age. Thus, different protocols have been designed exclusively to control disease progression in this frail patient population in which the use of a so-called 'gentle approach', and particularly the avoidance of ThaCyDex for refractory/relapsed multiple myeloma R García-Sanz et al intravenous treatments in favor of oral formulations, is an important goal. [20] [21] [22] 35, 36 Within this context, cyclophosphamide associated with steroids has proved to be a useful therapeutic approach. [20] [21] [22] With this background, we decided to add thalidomide to the oral cyclophosphamide and dexamethasone combination, in order to test first the toxicity/ feasibility of this regimen 19 and second the efficacy. The rationale for this new combination was that thalidomide could also offer a synergistic effect with dexamethasone and, in addition, could overcome the resistance of the MM to cytotoxic drugs. 23 In the preliminary results of a pilot study including 17 patients from a single institution, we demonstrated that the orally administered combination of thalidomide, cyclophosphamide and dexamethasone was feasible and resulted in a high response rate. 19 In the present paper, we report on an extension of the study including up to 71 patients from several institutions and with a longer follow-up. The results of the study not only confirmed that the regimen is well tolerated and highly effective (overall response rate of 89%, with a 57% CR/PR) but also, more importantly, that the results are reproducible in a multicenter setting with the possibility of obtaining long remissions in responding patients. Nevertheless, it should be noted that due to our exclusion criteria (life expectancy less than 3 months or severe cytopenias), these favorable results may not apply to all patients with advanced myeloma.
Several groups have reported on the efficacy of thalidomide and dexamethasone in refractory/relapsed MM patients, without significant toxicity. [24] [25] [26] Around 50% of patients (35-58%) achieve at least PR with this combination. Actually, it has recently been explored in newly diagnosed patients with a PR rate of 470%.
37,38
The addition of other drugs (i.e. alkylating agents) to thalidomide and dexamethasone is currently being explored by several groups. Thus, the combination of thalidomide, cyclophosphamide and dexamethasone was tested by the German group 27 as a second-line therapy with a high response rate (72% of PR). However, in this study, cyclophosphamide is used intravenously in intermediate doses, which results in a high toxicity (e.g. 83% of grade 4 neutropenia), which represents a major concern, particularly when dealing with patients older than 65 years of age. By contrast, the oral formulation of ThaCyDex used in the present trial was well tolerated, with a relatively low toxicity. A possible explanation for this low toxicity is that the dose escalation was only permitted in the absence of adverse effects. Actually, there were only five premature interruptions due to presumed toxicity, and all corresponded to patients already reported in the pilot study. 19 In addition, late toxicity was also acceptable, leading to protocol discontinuations in only four patients once they had been evaluated for response. This low toxicity rate is not surprising in the last reports using thalidomide, such as the one reported by Palumbo et al, 25 although the toxicity assignment in multicenter trials is not always perfect, and physicians using this protocol must be advised that a higher toxicity can be observed. Anyway, this toxicity is predicted to be lower than that observed with other protocols combining thalidomide, chemotherapy and sterois reporting a similar efficacy. For instance, Anagnostopoulos et al 39 combined thalidomide and dexamethasone (TD) with pulsed cyclophosphamide, obtaining a similar response rate (60% of PR), but with a high rate of severe neutropenia. TD has also been tested in combination with melphalan, 28 cyclophosphamide/etoposide 40 or doxorrubicin/vincristine, 41 providing a response rate of 54-86% PR. However, these other protocols have been tested in only a small series of patients or are restricted to younger patients due to its toxicity.
The response rate of the ThaCyDex protocol (89% of global response, 57% of partial response) is higher that that reported with thalidomide alone [11] [12] [13] [14] [15] [16] [17] [18] or in combination with dexamethasone. [24] [25] [26] However, we think that the major contribution of the current protocol is that the progression rate was relatively low, indicating that the responses obtained with this scheme are sustained. In fact, the EFS and OS reported here (57 and 66% at 2 years from the beginning of ThaCyDex treatment, respectively) are much higher than we have previously observed with other rescue protocols for relapsing/ refractory patients, mainly based on the use of high-dose dexamethasone. 42, 43 Of interest was the fact that the protocol was capable of achieving up to 10% CR, since none of these patients has relapsed so far. These results should favor the investigation of the ThaCyDex combination in other subsets of myeloma patients, such as newly diagnosed patients. An important comment is that our study excluded patients with a life expectancy p3 months, uncontrolled hypercalcemia and severe cytopenias, so no information about this type of patients can be provided.
Prognostic factors analysis identified b 2 microblobulin 44 mg/ l as an adverse prognostic factor both for response and survival. The presence of low platelet levels and refractory disease also conditioned a poor response, but did not influence survival. By contrast, age (465 years) emerged as an independent factor for survival. This is in agreement with a recent study published by Mileshkin et al, 44 who reported that patients 465 years have a significantly poor outcome with thalidomide as compared to younger patients. Other variables influencing survival, although not independent on multivariate analysis, were the presence of anemia, high LDH levels, poor ECOG and refractory disease.
A possible association has been reported between the presence of extramedullary myelomatous lesions and a poor response to thalidomide, 45, 46 including cases with extramedullary progression, although bone marrow response. 47 However, other authors have highlighted responses in this case to thalidomide. 48, 49 The present study shows that although patients with extramedullary myelomatous lesions may respond to ThaCyDex, this feature is associated with a poorer overall response and shorter survival, which indicates that the presence of this type of lesion is an adverse prognostic factor in patients treated with regimens containing thalidomide.
As mentioned above, ThaCyDex was well tolerated. DVT was present in only 7% of patients. This complication has been described in 3-5% of patients treated with thalidomide alone, 11 but it appears to be significantly more frequent when thalidomide is associated with dexamethasone or chemotherapy (21-28%). [50] [51] [52] [53] Thus, the incidence of DVT registered in our series (7%) is relatively low, and could be considered as another advantage of this oral regimen.
A remarkable event occurred in our series, with the sudden death of two patients. Some authors have underlined the possible arrhythmogenous effect of thalidomide. 54 Our two patients suffered cardiac arrest and had a previous history of severe cardiac disease, which would suggest that caution and close monitoring should be adopted in MM patients with underlying heart disease treated with thalidomide.
The current results shows that ThaCyDex not only affords a high response rate but also a durable response, particularly in relapsing patients with b 2 microglobulin p4 mg/dl and p65 years. This will be definitely defined by prospective, randomized, clinical trials that are now under design.
